A first-in-class EGFR-directed KRAS G12V selective inhibitor.

Lyla J Stanland: EnFuego Therapeutics, Inc, Morrisville, NC 27560, USA.
Hayden P Huggins: EnFuego Therapeutics, Inc, Morrisville, NC 27560, USA; Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Snehasudha S Sahoo: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
Alessandro Porrello: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
Yogitha Chareddy: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA; Curriculum in Genetics and Molecular Biology, UNC at Chapel Hill, Chapel Hill, NC, USA.
Salma H Azam: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Jillian L Perry: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; Center for Nanotechnology in Drug Delivery, Chapel Hill, NC, USA; Division of Chemical Biology and Medicinal Chemistry, UNC at Chapel Hill, Chapel Hill, NC, USA.
Pradeep S Pallan: Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
Kristina Whately: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
Lincy Edatt: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
William D Green: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC at Chapel Hill, Chapel Hill, NC, USA.
Matthew C Fleming: Division of Chemical Biology and Medicinal Chemistry, UNC at Chapel Hill, Chapel Hill, NC, USA; Center for Integrative Chemical Biology and Drug Discovery, Chapel Hill, NC, USA.
Jonah Im: EnFuego Therapeutics, Inc, Morrisville, NC 27560, USA; Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Christina Gutierrez-Ford: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Imani Simmons: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Alyaa Dawoud: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
Katherine I Zhou: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA; Division of Medical Oncology, Duke University, Durham, NC 27705, USA.
Vandanaa Jayaprakash: EnFuego Therapeutics, Inc, Morrisville, NC 27560, USA; Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Rani S Sellers: Department of Pathology and Laboratory Medicine, UNC at Chapel Hill, Chapel Hill, NC, USA.
Gabriela de la Cruz: Department of Pathology and Laboratory Medicine, UNC at Chapel Hill, Chapel Hill, NC, USA.
Albert Wielgus: Department of Pathology and Laboratory Medicine, UNC at Chapel Hill, Chapel Hill, NC, USA.
Justin Milner: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC at Chapel Hill, Chapel Hill, NC, USA.
Martin Egli: Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
Albert A Bowers: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA; Division of Chemical Biology and Medicinal Chemistry, UNC at Chapel Hill, Chapel Hill, NC, USA; Center for Integrative Chemical Biology and Drug Discovery, Chapel Hill, NC, USA; Department of Chemistry, UNC at Chapel Hill, Chapel Hill, NC, USA.
Chad V Pecot: Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA; Division of Hematology/Oncology, UNC at Chapel Hill, Chapel Hill, NC, USA. Electronic address: pecot@email.unc.edu.

OpenLB
Open Library of Bioscience

Abstract

Keywords

References

Grants

MeSH Term

Chemicals

Word Cloud

Similar Articles

Cited By

OpenLB Open Library of Bioscience

A first-in-class EGFR-directed KRAS G12V selective inhibitor.

Abstract

Keywords

References

Grants

MeSH Term

Chemicals

Word Cloud

Similar Articles

Cited By

OpenLB
Open Library of Bioscience